2011 Fiscal Year Final Research Report
Basic Research for elucidation of chemo-resistance in mucinous adenocarcinoma cell.
| Project/Area Number |
22791532
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Tottori University |
|---|
Principal Investigator |
SATO Shinya 鳥取大学, 医学部附属病院, 助教 (10423261)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Keywords | 婦人科腫瘍学 |
|---|
| Research Abstract |
(1) A negligible increase in inhibition of cell growth induced by CDDP was detected in the presence of PI3K inhibitor in all cell lines. We observed a decrease the cytotoxicity of CDDP when CDDP was combined with MEK inhibitor. Interestingly, cell growth was dramatically suppressed when CDDP was combined with PMA in all the cells that were resistant to CDDP. After treatment with CDDP and PMA, the proportion of the cells in G0/G1 phase and G2/M phase were decreased, and the proportion of cells in the S-phase fraction was dramatically increased, and then the cell cycle distribution was shifted to the subG1 phase in the CDDP resistant cells.
(2) Treatment with CDDP and PMA prolonged survival in nude mice bearing ovarian cancer cells.
|
-
-
[Journal Article] Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun2011
Author(s)
Itamochi H, Oishi T, Shimada M, Sato S, Uegaki K, Naniwa J, Sato S, Nonaka M, Terakawa N, Kigawa J, Harada T
Volume
17(14)
Pages
4742-50
Peer Reviewed
-
-
-
-
-
-
-
-
[Presentation] Inhibiting the mTOR pathway synergistically enhances etoposide-induced cytotoxicity by upregulating c-Jun in ovarian cancer cell2011
Author(s)
Itamochi H, Nonaka M, Sato S, Uegaki K, Naniwa J, Sato S, Shimada M, Oishi T, Terakawa N, Kigawa J, Harada T
Organizer
102th Annual Meeting of American Association for Cancer Research
Place of Presentation
Orlando
Year and Date
20110402-0406
-
[Presentation] Association for Cancer Research2011
Author(s)
Oishi T, Itamochi H, Nonaka M, Sato S, Naniwa J, Uegaki K, Sato S, Shimada M, Terakawa N, Harada T, Kigawa J
Organizer
102th Annual Meeting of American
Place of Presentation
Orlando
Year and Date
20110402-0406
-
-
[Presentation] Activation of the MEK/ERK pathway may overcomes the cisplatin-resistance in ovarian carcinoma cells2010
Author(s)
Itamochi H, Nonaka M, Kawaguchi W, Uegaki K, Naniwa J, Sato S, Shimada M, Oishi T, Terakawa N, Harada T, Kigawa J
Organizer
IGCS 13th Biennial Meeting
Place of Presentation
Prague
Year and Date
20101023-1026
-
-
-
-
-
-
-
-
[Presentation] Activation of the ERK pathways overcome the cisplatin-resistance in ovarian carcinoma cells2010
Author(s)
Nonaka M, Itamochi H, Kawaguchi W, Uegaki K, Naniwa J, Sato S, Shimada M, Oishi T, Terakawa N, Kigawa J, Harada T
Organizer
101th Annual Meeting of American Association for Cancer Research
Place of Presentation
Washington DC
Year and Date
20100417-0421
